Skip to main content

Advertisement

SpringerLink
Log in

Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Decline of body weight and body mass index (BMI) with aging is a major risk factor for osteoporosis and fracture, suggesting that treatment for osteoporosis may affect body composition. However, the effects of treatment for osteoporosis on body composition are not well known. The present study aimed to identify the relationship between raloxifene treatment and body composition markers. We measured bone mineral density (BMD), body composition, and bone remodeling markers in 236 Japanese postmenopausal women with raloxifene treatment (N = 50) and without treatment by any osteoporosis drug (N = 186) for 5 years and analyzed the relationship of these with BMD, BMI, body weight, and biochemical markers. The mean (SD) age of the participants was 65.5 (9.3) years. Percent-changes in body weight and BMI were significantly different between women taking raloxifene and those not taking any osteoporosis drugs (P = 0.03 and 0.048, respectively). Raloxifene treatment was a significant independent determinant of body weight and BMI. Long-term treatment with raloxifene prevents age-related weight loss.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Samson MM, Meeuwsen IBAE, Crowe A, Dessens JAG, Duursma SA, Verhaar HJJ (2010) Differences in variables of muscle strength and functional mobility in healthy subjects in relation to age, height and body weight. Age Ageing 29:235–242

    Article  Google Scholar 

  2. Kallman DA, Plato CC, Tobin JD (1990) The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol 45:M82–M88

    Article  CAS  PubMed  Google Scholar 

  3. Panotopoulos G, Raison J, Ruiz JC, Guy-Grand B, Basdevant A (1997) Weight gain at the time of menopause. Hum Reprod 12:126–133

    Article  PubMed  Google Scholar 

  4. Di Carlo C, Tommaselli GA, Sammantino A, Bifulco G, Nasti A, Nappi C (2004) Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause 11:466–473

    Article  PubMed  Google Scholar 

  5. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L (1984) Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gothenburg. Sweden. Br Med J (Clin Res Ed) 289:1257–1261

    Article  CAS  Google Scholar 

  6. Hagberg JM, Zmuda JM, McCole SD, Rodgers KS, Wilund KR, Moore GE (2000) Determinants of body composition in postmenopausal women. J Gerontol A Biol Sci Med Sci 55:M607–M612

    Article  CAS  PubMed  Google Scholar 

  7. Phillips SK, Rook KM, Siddle NC, Bruce SA, Woledge RC (1993) Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Lond) 84:95–98

    Article  CAS  Google Scholar 

  8. Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738

    Article  CAS  PubMed  Google Scholar 

  9. Greeves JP, Cable NT, Reilly T, Kingsland C (1999) Changes in muscle strength in women following the menopause: a longitudinal assessment of the efficacy of hormone replacement therapy. Clin Sci (Lond) 97:79–84

    Article  CAS  Google Scholar 

  10. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  CAS  PubMed  Google Scholar 

  11. Khovidhunkit W, Shoback DM (1999) Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 130:431–439

    Article  CAS  PubMed  Google Scholar 

  12. Ott SM, Oleksik A, Lu Y, Harper K, Lips P (2002) Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 17:341–348

    Article  CAS  PubMed  Google Scholar 

  13. Jolly EE, Bjarnason NH, Neven P et al (2003) Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 10:337–344

    Article  PubMed  Google Scholar 

  14. Ivergård M, Ström O, Borgström F, Burge RT, Tosteson AN, Kanis J (2010) Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone 47:966–974

    Article  PubMed  Google Scholar 

  15. Silverman SL, Chines AA, Kendler DL et al (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23:351–363

    Article  CAS  PubMed  Google Scholar 

  16. Jacobsen DE, Samson MM, Emmelot-Vonk MH, Verhaar HJ (2010) Raloxifene and body composition and muscle strength in postmenopausal women: a randomized, double-blind, placebo-controlled trial. Eur J Endocrinol 162:371–376

    Article  CAS  PubMed  Google Scholar 

  17. Francucci CM, Daniele P, Iori N, Camilletti A, Massi F, Boscaro M (2005) Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women. J Endocrinol Invest 28:623–631

    Article  CAS  PubMed  Google Scholar 

  18. Shiraki M, Kuroda T, Shiraki Y, Aoki C, Sasaki K, Tanaka S (2010) Effects of bone mineral density of the lumbar spine and prevalent vertebral fractures on the risk of immobility. Osteoporos Int 21:1545–1551

    Article  CAS  PubMed  Google Scholar 

  19. Urano T, Shiraki M, Ouchi Y, Inoue S (2012) Association of circulating sclerostin levels with fat mass and metabolic disease-related markers in Japanese postmenopausal women. J Clin Endocrinol Metab 97:E1473–E1477

    Article  CAS  PubMed  Google Scholar 

  20. Uenishi K, Ishida H, Nakamura K (2008) Development of a simple food frequency questionnaire to estimate intakes of calcium and other nutrients for the prevention and management of osteoporosis. J Nutr Sci Vitaminol (Tokyo) 54:25–29

    Article  CAS  Google Scholar 

  21. Han TS, Wu FC, Lean ME (2013) Obesity and weight management in the elderly: a focus on men. Best Pract Res Clin Endocrinol Metab 27:509–525

    Article  CAS  PubMed  Google Scholar 

  22. Migliaccio S, Greco EA, Aversa A, Lenzi A (2014) Age-associated (cardio)metabolic diseases and cross-talk between adipose tissue and skeleton: endocrine aspects. Horm Mol Biol Clin Investig 20:25–38

    CAS  PubMed  Google Scholar 

  23. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR (2008) Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond) 32:949–958

    Article  CAS  Google Scholar 

  24. Lobo RA (2008) Metabolic syndrome after menopause and the role of hormones. Maturitas 60:10–18

    Article  CAS  PubMed  Google Scholar 

  25. Polotsky HN, Polotsky AJ (2010) Metabolic implications of menopause. Semin Reprod Med 28:426–434

    Article  PubMed  Google Scholar 

  26. Kristensen K, Pedersen SB, Vestergaard P, Mosekilde L, Richelsen B (1999) Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women. J Endocrinol 163:55–62

    Article  CAS  PubMed  Google Scholar 

  27. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR (2001) Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 39:125–132

    Article  CAS  PubMed  Google Scholar 

  28. Spiro AS, Khadem S, Jeschke A, Marshall RP, Pogoda P, Ignatius A, Amling M, Beil FT (2013) The SERM raloxifene improves diaphyseal fracture healing in mice. J Bone Miner Metab 31:629–636

    Article  CAS  PubMed  Google Scholar 

  29. Meli R, Pacilio M, Raso GM et al (2004) Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats. Endocrinology 145:3115–3121

    Article  CAS  PubMed  Google Scholar 

  30. Moran AL, Nelson SA, Landisch RM, Warren GL, Lowe DA (2007) Estradiol replacement reverses ovariectomy-induced muscle contractile and myosin dysfunction in mature female mice. J Appl Physiol 102:1387–1393

    Article  CAS  PubMed  Google Scholar 

  31. Greising SM, Baltgalvis KA, Lowe DA, Warren GL (2009) Hormone therapy and skeletal muscle strength: a meta-analysis. J Gerontol A Biol Sci Med Sci 64:1071–1081

    Article  PubMed  Google Scholar 

  32. Lowe DA, Baltgalvis KA, Greising SM (2010) Mechanisms behind estrogen’s beneficial effect on muscle strength in females. Exerc Sport Sci Rev 38:61–67

    Article  PubMed  PubMed Central  Google Scholar 

  33. Messier V, Rabasa-Lhoret R, Barbat-Artigas S, Elisha B, Karelis AD, Aubertin-Leheudre M (2011) Menopause and sarcopenia: a potential role for sex hormones. Maturitas 68:331–336

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Japan Society for the Promotion of Science (25293214) and the Ministry of Culture, Education, Sports, Science and Technology of Japan. This work was also supported in part by a Grant-in-Aid from Astellas Foundation for Research on Metabolic Disorders. We appreciate all the volunteers for precious clinical data and samples.

Author information

Author notes

    Authors and Affiliations

    1. Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bumkyo-ku, Tokyo, 113-8655, Japan

      Tomohiko Urano & Satoshi Inoue

    2. Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan

      Tomohiko Urano & Satoshi Inoue

    3. Research Institute and Practice for Involutional Diseases, Nagano, Japan

      Masataka Shiraki

    4. Public Health Research Foundation, Tokyo, Japan

      Tatsuhiko Kuroda

    5. Division of Clinical Trial, Design and Management, Translational Research Center, Kyoto University, Kyoto, Japan

      Shiro Tanaka

    6. Division of Nutritional Physiology, Kagawa University, 3-9-21 Chiyoda, Sakaido, Saitama, 350-0288, Japan

      Kazuhiro Uenishi

    7. Research Center for Genomic Medicine, Saitama Medical School, Saitama, 350-1241, Japan

      Satoshi Inoue

    Authors
    1. Tomohiko Urano
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Masataka Shiraki
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Tatsuhiko Kuroda
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Shiro Tanaka
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Kazuhiro Uenishi
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Satoshi Inoue
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Satoshi Inoue.

    Ethics declarations

    Conflict of interest

    Tatsuhiko Kuroda is an employee of Asahi Kasei Pharma. Tomohiko Urano, Masataka Shiraki, Shiro Tanaka, Kazuhiro Uenishi and Satoshi Inoue declare that they have no conflict of interest.

    Additional information

    T. Urano and M. Shiraki contributed equally to this work.

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Urano, T., Shiraki, M., Kuroda, T. et al. Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women. J Bone Miner Metab 35, 108–113 (2017). https://doi.org/10.1007/s00774-015-0733-8

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00774-015-0733-8

    Keywords

    Search

    Navigation